Article

Systemic biomarkers of inflammation and haemostasis in patients with chronic necrotizing pulmonary aspergillosis

Research Institute for Internal Medicine, University of Oslo, Oslo, Norway. .
BMC Infectious Diseases (Impact Factor: 2.56). 06/2012; 12:144. DOI: 10.1186/1471-2334-12-144
Source: PubMed

ABSTRACT The purpose of this study was to investigate mediators of inflammation and haemostasis in patients with chronic necrotizing pulmonary aspergillosis (CNPA), a locally, destructive process of the lung due to invasion by Aspergillus species.
Measurements of selected biomarkers in 10 patients with CNPA and 19 healthy, matched controls were performed with enzyme-linked immunosorbent assay (ELISA) and multiplex methodology. The gene expressions of relevant biomarkers were analyzed with real-time quantitative RT-PCR.
Increased concentrations of circulating mediators of inflammation interleukin (IL)-6, IL-8, RANTES, TNF-α, ICAM-1 and mediators involved in endothelial activation and thrombosis (vWF, TF and PAI-1) were observed in patients with CNPA. The concentration of the anti-inflammatory cytokine IL-10 was increased both in plasma and in PBMC in the patient population. The gene expression of CD40L was decreased in PBMC from the patient group, accompanied by decreased concentrations of soluble (s) CD40L in the circulation.
The proinflammatory response against Aspergillus may be counteracted by reduced CD40L and sCD40L, as well as increased IL-10, which may compromise the immune response against Aspergillus in patients with CNPA.

Download full-text

Full-text

Available from: Frank Brosstad, Jun 27, 2015
0 Followers
 · 
300 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic pulmonary aspergillosis (CPA) is a group of consuming diseases usually presenting with prolonged and relapsing cough, dyspnoea and weight loss. Acute symptoms such as haemoptysis and bronchial or pulmonary haemorrhage may occasionally occur. CPA affects patients with underlying pulmonary conditions, for example, chronic obstructive pulmonary disease or mycobacteriosis or common immunosuppressive conditions such as diabetes. Precise epidemiology is unknown, and while prevalence is considered low the chronic and relapsing nature of the disease challenges the treating physician. Diagnostics largely rely on serologic Aspergillus precipitins and findings on thoracic computed tomography. The latter are manifold comprising cavity formation, pleural involvement and sometimes aspergilloma. Other markers for aspergillosis are less helpful, in part due to the non- or semi-invasive nature of these forms of Aspergillus infection. Various antifungals were shown to be effective in CPA treatment. Azoles are the most frequently applied antifungals in the outpatient setting, but are now compromised by findings of Aspergillus resistance. Long-term prognosis is not fully elucidated and may be driven by the underlying morbidities. Prospective registry-type studies may be suitable to systematically broaden our CPA knowledge base. This article gives an overview of the available literature and proposes a clinical working algorithm for CPA management.
    Mycoses 12/2013; 57(5). DOI:10.1111/myc.12152 · 1.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: item page Item Page Preface 1 6. Aspergillosis in animals 91 1.Introduction 4 6.1. Aspergillosis in dogs 91 2.Historical 5 6.2. Aspergillosis in cats 94 3. Nomenclature and classification 11 6.3. Aspergillosis in horses 96 4. Description of important aspergilli 17 6.4. Aspergillosis in cattle 98 4.1. Aspergillus Section Restricti 17 6.5. Aspergillosis in Sheep and goats 100 4.2. Aspergillus Section Cervini 18 6.6. Aspergillosis in pigs 104 4.3. Aspergillus section Nigri 19 6.7. Aspergillosis in camels 104 4.4. Aspergillus section Candidi 23 6.8. Aspergillosis in American bisons 105 4.5. Aspergillus section Usti 25 6.9. Aspergillosis in monkeys 106 4.6. Aspergillus section Versicolores 26 6.10. Aspergillosis in deers 106 4.7. Aspergillus section Sparsi 30 6.11. Aspergillosis in rabbits 107 4.8.Aspergillus Section: Aspergillus 31 6.12. Aspergillosis in guinea-pigs 108 4.9. Aspergillus section Terrei 35 4.13. Aspergillosis in lesser blind mole rats 108 4. 10. Aspergillus Section Flavipedes 36 6.14. Aspergillosis in dolphins 109 4. 11. Section: Circumdati 39 7. Aspergillosis in birds 110 4. 12. Aspergillus section Flavi 40 7. 1. Aspergillosis in poultry 110 4.13. Aspergillus Section: Cremei 45 7.2. Aspergillosis in wild birds: 112 4.14. Aspergillus section Fumigati 46 7.2.1. Aspergillosis in penguins 112 4. 15. Aspergillus Section:Clavati 49 7.2.2. Aspergillosis in parrots 114 4. 16. Aspergillus Section:Nidulantes 50 7.2.3. Aspergillosis in quails 115 4. 17. Aspergillus Section:Ornati 52 7.2.4. Aspergillosis in ostrich 116 4. 18. Aspergillus sect. Aeni 52 7.2.5. Aspergillosis in red-tailed hawk 117 5. Aspergillosis in man 7.2.6. Aspergillosis in Red-billed Toucan 117 5.1. Pulmonary aspergillosis 7.2.7. Aspergillosis in Snow Owl 118 5.2. Cerebral aspergillosis 71 7.2.8. Aspergillosis in Goshawk 118 5.3. Cutaneous aspergillosis 73 7.2.9. Aspergillosis in Cormorants 119 5.4. Aspergillus Onychomycosis 75 7.2.10. Aspergillosis in swans 119 5. 5. Ocular aspergillosis 76 7.2.11. Aspergillosis in kiwi 120 5.6. Aspergillus sinusitis 78 8. Laboratory diagnosis of aspergillosis 123 5.7. Paranasal sinuses aspergillosis 79 8.1. Direct microscopic examination 123 5.8. Otoaspergillosis 81 8.2. Isolation and identification 128 5.9. Aspergillus endocarditis 82 8.3.Molecuar identification of aspergilli 132 5.10. Aspergillus thyroiditis 84 8.4. Serological techniques 135 5.11. Hepatic aspergillosis 85 9. Treatment of aspergillosis 140 5.12. Gastrointestinal aspergillosis 86 10. References 143 5.13. Urinary tract aspergillosis 87 5.13. Aspergillus osteomyelitis 88